Abstract 444P
Background
High-dose cytarabine (HDAC) is used to treat hematologic malignancies. Eye disorders are common side effects caused by cytarabine (AraC) being transported from the blood into tear fluid. In our institution, four times a day (FM4) or six times a day (FM6) of 0.1% fluorometholone eye drops are used to prevent AraC-induced eye disorders. In this study, we investigated the prophylactic effects of FM6 or FM4 to prevent AraC-induced eye disorders retrospectively.
Methods
We targeted the patients who were hospitalized and administered with HDAC twice a day at a dose of 1 g/m2 or more between April 2011 and March 2018. The patients received 0.1% fluorometholone eye drops in a both eyes from the start of HDAC dose to 48 hours after the end of HDAC dose. We investigated the incidence of eye disorders or grade based on the medical records from the start of HDAC dose until 7 days after the end of HDAC dose, retrospectively.
Results
There were 36 patients of FM4 and 44 of FM6 for prevention of AraC-induced eye disorders, respectivity. The incidence of eye disorders was 6 (16.7%) in FM4 and 7 (15.9%) in FM6. No Grade 3 eye disorders occurred in both groups. The number of courses of the eye disorder appeared for FM4 and FM6 were 1 and 2 courses. In addition, the median of AraC cumulative dose at the time of the eye disorders appeared for FM4 and FM6 was 10 (4-20) g/m2 and 20 (6-42) g/m2.
Conclusions
There is no difference in preventive effect between FM4 and FM6 for AraC-induced eye disorders. Further, FM4 is considered useful and a convenient method for the prevention of AraC-induced eye disorders.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
458P - Mutation tracking in circulating tumour DNA predicts relapse in completely resected EGFR-mutated NSCLC
Presenter: Martin Filipits
Session: Poster display session
Resources:
Abstract
460P - Mendelian randomization study showed no causality between metformin use and lung cancer risk
Presenter: Jiayi Shen
Session: Poster display session
Resources:
Abstract
461P - Blood trace minerals and lung cancer: A Mendelian randomization study
Presenter: Wei Xian
Session: Poster display session
Resources:
Abstract
463P - Prediction of invasiveness in lung adenocarcinoma using machine learning algorithm based on 3D-CT imaging
Presenter: Yusuke Saeki
Session: Poster display session
Resources:
Abstract
459P - Fish intake, dietary polyunsaturated fatty acids, and lung cancer: systematic review and dose-response meta-analysis of 1.7 million men and women
Presenter: Chao Cao
Session: Poster display session
Resources:
Abstract
462P - Usefulness for prevention of postoperative cerebrovascular complications in patients with lung cancer using carotid ultrasonography
Presenter: Sadanori Takeo
Session: Poster display session
Resources:
Abstract
468P - Histological type analysis of 10-year follow-up of WJTOG0105: A phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer
Presenter: Masahiro Tsuboi
Session: Poster display session
Resources:
Abstract
469P - Comparison of combined chemoradiotherapy regimens; Paclitaxel plus carboplatin and cisplatin plus etoposide for locally advanced non-small cell lung cancer: A randomised phase III trial
Presenter: Alper Ata
Session: Poster display session
Resources:
Abstract
472P - Integration of expression rate and absolute cell counts of PD-1+ stromal tumour-infiltrating lymphocytes: Prognostic significance in esophageal squamous cell carcinoma
Presenter: Qingkun Song
Session: Poster display session
Resources:
Abstract
467P - The free-circulating mtDNA copies number in plasma of patients with NSCLC
Presenter: Olga Bulgakova
Session: Poster display session
Resources:
Abstract